You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts

Article info

Article menu
XML
Interstitial lung disease
Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts

Authors

  • Carlos Machahua Department for Pulmonary Medicine, Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Bern, SwitzerlandDepartment of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  • Sabina A. Guler Department for Pulmonary Medicine, Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Bern, SwitzerlandDepartment of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  • Michael P. Horn Department of Clinical Chemistry, Inselspital University Hospital Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  • Lurdes Planas-Cerezales Unit of interstitial lung disease, Department of Pneumology, University Hospital of Bellvitge L’Hospitalet de Llobregat, Barcelona, SpainPneumology Research Group, Institut D’Investigació Biomedica de Bellvitge IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Ana Montes-Worboys Pneumology Research Group, Institut D’Investigació Biomedica de Bellvitge IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Thomas K. Geiser Department for Pulmonary Medicine, Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Bern, SwitzerlandDepartment of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  • Maria Molina-Molina Unit of interstitial lung disease, Department of Pneumology, University Hospital of Bellvitge L’Hospitalet de Llobregat, Barcelona, SpainPneumology Research Group, Institut D’Investigació Biomedica de Bellvitge IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Manuela Funke-Chambour Department for Pulmonary Medicine, Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Bern, SwitzerlandDepartment of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Manuela Funke-Chambour; manuela.funke-chambour{at}insel.ch
View Full Text

Citation

Machahua C, Guler SA, Horn MP, et al
Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts
BMJ Open Respiratory Research 2021;8:e000827. doi: 10.1136/bmjresp-2020-000827

Publication history

  • Received November 6, 2020
  • Revised December 11, 2020
  • Accepted December 13, 2020
  • First published January 15, 2021.
Online issue publication 
July 13, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.